Abaloparatide (Tymlos) vs PE 22-28
Updated August 24, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Abaloparatide (Tymlos) and PE 22-28 (also searched as PE 22-28 vs Abaloparatide (Tymlos)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Abaloparatide (Tymlos) centers on healing, while PE 22-28 leans toward metabolic. On indexed research, PE 22-28 is ahead (Abaloparatide (Tymlos): 27 studies, Human clinical; PE 22-28: 29, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Abaloparatide (Tymlos) is strongest for healing; PE 22-28 for metabolic.
- •Evidence: Abaloparatide (Tymlos) Human clinical (27 studies) vs PE 22-28 Human evidence (29).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
PTH1R activation | Osteoporosis treatment
Metabolic regulation | Gestational diabetes
Abaloparatide (Tymlos) vs PE 22-28: side-by-side
| Metric | Abaloparatide (Tymlos) | PE 22-28 |
|---|---|---|
| Class | Healing | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 27 | 29 |
| Research level | FDA Approved | Limited Research |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 2.0 |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 2.0 | 3.0▲ |
| Neuro & mood | 0.0 | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0▲ | 1.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Abaloparatide (Tymlos) | PE 22-28 |
|---|---|---|
| Mechanism | PTH1R agonist | — |
| Route | Subcutaneous injection | — |
| Half-life | ~30 min | — |
| Time to peak | 4 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Abaloparatide (Tymlos)?
Abaloparatide (Tymlos) is a synthetic PTHrP analog and FDA-approved anabolic agent for osteoporosis, building bone via selective PTH1R activation.
Full Abaloparatide (Tymlos) profile, mechanism & studies →What is PE 22-28?
PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Abaloparatide (Tymlos) | 4.0/5 effect signal |
| Muscle | Abaloparatide (Tymlos) | 1.0/5 effect signal |
| Metabolic | PE 22-28 | 3.0/5 effect signal |
| Inflammation | Even | Both ~1.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Abaloparatide (Tymlos) and PE 22-28?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Abaloparatide (Tymlos) vs PE 22-28: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Abaloparatide (Tymlos) has 27 approved studies indexed (Human clinical), and PE 22-28 has 29 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Abaloparatide (Tymlos) or PE 22-28 better?
It depends on your goal. Abaloparatide (Tymlos) is strongest for healing; PE 22-28 for metabolic. PE 22-28 has more indexed studies (29). See the goal-by-goal breakdown above.
Is Abaloparatide (Tymlos) or PE 22-28 better for weight loss?
PE 22-28 shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Abaloparatide (Tymlos) or PE 22-28 better for muscle?
Abaloparatide (Tymlos) leads on the muscle & body-composition axis (1.0/5).
Which has more research, Abaloparatide (Tymlos) or PE 22-28?
Abaloparatide (Tymlos) has 27 approved studies indexed (Human clinical); PE 22-28 has 29 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Abaloparatide (Tymlos) and PE 22-28?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Abaloparatide (Tymlos) vs PE 22-28?
Abaloparatide (Tymlos): no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Abaloparatide (Tymlos) or PE 22-28 FDA-approved?
Abaloparatide (Tymlos) is FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PE 22-28 better than Abaloparatide (Tymlos)?
For metabolic, PE 22-28 has the edge; for healing, Abaloparatide (Tymlos) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed August 24, 2026.